title: Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
abstract: OBJECTIVE
  To evaluate the efficacy and the toxicity profile of the sequential administration of doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).
  
  
  METHODS
  Eighty-one patients received a total of 436 cycles of chemotherapy: 236 of doxorubicin (75 mg/m2) and 200 of docetaxel (100 mg/m2 every 21 days). The first 35 patients received doxorubicin every 14 days with G-CSF support, and in the other 46 cases doxorubicin was administered every 21 days without G-CSF.
  
  
  RESULTS
  After entire treatment the overall response rate was 65% (18 complete responses). With a median follow-up of 19 months (range, 1-48 months), the median time to progression was 11.3 months and the median survival time was 31 months. As expected, febrile neutropenia was the most important toxicity and it appeared in 26 cycles (6%) and 19 patients (23%). In the patients that received doxorubicin every 14 days, the febrile neutropenia incidence was higher during docetaxel treatment, especially after its first administration.
  
  
  CONCLUSIONS
  The dose and schedule of doxorubicin and docetaxel used in this trial seems to be active in first-line treatment of patients with MBC. The toxicity profile appears to be better than observed with concomitant schedules.
authors.affiliation: Service of Oncology, Hospital Clínico Universitario, Málaga, Spain. oncologia98@yahoo.com
authors.forename: E
authors.initials: E
authors.lastname: Alba
authors.forename: N
authors.initials: N
authors.lastname: Ribelles
authors.forename: A
authors.initials: A
authors.lastname: Antón
authors.forename: R
authors.initials: R
authors.lastname: Pérez-Carrión
authors.forename: J M
authors.initials: JM
authors.lastname: López-Vega
authors.forename: M
authors.initials: M
authors.lastname: Llanos
authors.forename: A
authors.initials: A
authors.lastname: Pelegri
authors.forename: J
authors.initials: J
authors.lastname: Florián
authors.forename: M
authors.initials: M
authors.lastname: Menéndez
authors.forename: M J
authors.initials: MJ
authors.lastname: Godes
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D010166:Palliative Care; D011446:Prospective Studies; D013030:Spain; D016019:Survival Analysis; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel